Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04469764 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Jul 1, 2026 to Jul 1, 2027
    • Study completion date: Jul 1, 2027 to Jul 1, 2028
    v13
  2. Primary completion date: Jul 1, 2025 to Jul 1, 2026
    • Study completion date: Jul 1, 2026 to Jul 1, 2027
    v12
  3. Re-verified, no change to tracked fieldsv11
  4. Primary completion date: Jul 1, 2024 to Jul 1, 2025
    • Study completion date: Jul 1, 2025 to Jul 1, 2026
    v10
  5. 4 versions Re-verified since Jul 21, 2021, no change to tracked fieldsv6-v9
Show 4 earlier versionsHide 4 earlier versions
  1. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Nov 1, 2020 to Oct 16, 2020
    • Site details revised
    v5
  2. Start date: Sep 1, 2020 to Nov 1, 2020v4
  3. Collaborators expanded, about 4 wordsv3
  4. Start date: Jul 10, 2020 to Sep 1, 2020
    • Collaborators shortened, about 4 words
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase II trial studies how well abemaciclib works in treating patients with ovarian or endometrial cancer that has an activation of the CDK4/6 pathway and that has come back (recurrent). Abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving abemaciclib may work better for the treatment of recurrent ovarian and endometrial cancer.
Trial Details
NCT Number NCT04469764
Lead Sponsor Jonsson Comprehensive Cancer Center
Collaborators: Eli Lilly and Company
Conditions
(from sponsor)		 Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Related terms Endometrial Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms
Enrollment 32 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov